Conclusions: The progression of UA to RA is apparently ameliorated in RF positive females who received conventional HRT and oral E3 treatment. Although the numbers were smaller, a significant protective effect was not observed in ACPA positive UA females, because they developed RA before menopause. Our observations suggest that HRT in peri- and post-menopausal and oestrogen (E3) in pre-menopausal females with RF and ACPA positive UA may be important in ameliorating the progression of UA to RA.

REFERENCES:

Acknowledgements: We thank Dr Koyama for his advices and encouragement.

Disclosure of Interest: None declared


THU0696

IS AUTOIMMUNITY RELATED TO NAILFOLD VIDEOCAPILLAROSCOPY PATTERNS PROGRESSION? DATA FROM A TERTIARY CENTRE


Background: Nailfold videocapillaroscopy (NVC) is a non-invasive technique that allows to evaluate the structure and distribution of capillaries in the nail microcirculation. (Ab) detected in the patients who undergo follow-up NVCs and the progression from non-specific patterns to patterns of late scleroderma.

Objectives: Our objective was to investigate the relation between the autoantibodies (Ab) detected in the patients who undergo follow-up NVCs and the progression from non-specific patterns to patterns of late scleroderma.

Methods: Longitudinal, observational and descriptive study that includes patients with at least two NVCs, between June 2012 and December 2016 in the Rheumatology service of a tertiary centre. We collected demographics data, number of NVCs performed, Ab positivity, as well as the NVCs patterns. The relationship between the basal autoimmunity and the progression of the NVCs patterns during the follow-up period, defining progression from non-specific patterns to patterns of scleroderma to late scleroderma.

Results: 473 patients were included, 115 had two or more NVCs performed, 104 women (90.51%). Of these, 40 (34.75%) had a third NVC, 9 (7.82%) a fourth and only two patients a fifth. Regarding the Ab registered in patients before the first NVC, 27 patients did not present positivity to any Ab (23.47%), 28 isolated ANA + (24.34%), 33 Anticentromere+with or without ANA (28.69%), 7 patients Anti-scl-70 + with or without ANA (6.08%), 10 patients Anti-Ro or Anti-La with or without ANA (8.69) and 10 patients presented other types of antibodies than those mentioned (11.3%). The most frequent pattern in the first NVC was non-specific mild alterations (49 cases) in 42.6%, followed by normal pattern20 in 17.39%, early scleroderma14 in 16.52%, non-specific moderate lesions17 and pattern of late scleroderma10 There was a progression from lower to higher severity in 25 NVCs, 88 maintained a similar pattern and 2 NVCs presented significant regression (table 2).

Abstract THU0696 – Table 1. Baseline diagnosis before first NVC.

Baseline diagnosis n: %

Primary Raynaud Phenomenon 56 48.27
Systemic scleroderma 27 23.27
Systemic Lupus Erythematosus 8 6.89
Undifferentiated connective tissue 8 6.89
Mixed Connective Tissue 4 3.41
Disease
Dermatomyositis 2 1.72
Others 10 8.62

Abstract THU0696 – Table 2. Patients whose NVC progresses, patterns and related autoantibodies.

<table>
<thead>
<tr>
<th>n:25 Autoantibodies (%)</th>
<th>Progression</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/2: NMI to ES, 1/2: NML to LS</td>
<td>2 (8%) Ninguno</td>
</tr>
<tr>
<td>4 ANA+</td>
<td>2/4: NMI to AS, 1/4: NML to ES</td>
</tr>
<tr>
<td>±Anticentrómero</td>
<td></td>
</tr>
<tr>
<td>3 ANA±AntiScl70+</td>
<td>1/3: NML to AS, 1/3: ES to LS, 1/3: ES to AS</td>
</tr>
<tr>
<td>3 ANA±Anti-Ro/</td>
<td></td>
</tr>
<tr>
<td>Anti-La+</td>
<td>2/3: NML to ES, 1/3: ES to LS</td>
</tr>
<tr>
<td>3 Others</td>
<td></td>
</tr>
</tbody>
</table>

NVC patterns: Normal (N), non-specific mild alterations (NMI), non-specific moderate lesions (NML), Early scleroderma (ES), Active scleroderma (AS) y Late scleroderma (LS)

Conclusions: Autoimmunity does not seem to influence on the degree of progression of NVCs patterns. The association between positive ANA with anticientromere +or not, it is the most frequently combination related to the progression of such patterns.

REFERENCES:

Disclosure of Interest: None declared


THU0697

RISK OF MAJOR CONGENITAL MALFORMATIONS ASSOCIATED WITH EXPOSURE TO CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIHEUMATIC DRUGS IN WOMEN WITH INFLAMMATORY ARTHRITIS: A POPULATION-BASED COHORT STUDY

M.A. De Vega1,2, E.C. Sayre3, N.W. Tsao1,2, A. Howren1. 1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, 2Arthritis Research Canada, Richmond, Canada

Background: Prior studies of perinatal exposure to conventional synthetic disease modifying antirheumatic drugs (csDMARDs) and risk of major congenital malformations (MCM) have often lacked comparator groups and specific timing of medication exposure.

Objectives: To evaluate the association between csDMARD use before and during pregnancy and risk of MCM.

Methods: We conducted a population-based, retrospective cohort study using British Columbia administrative data from 01/01/2002 and 12/31/2012 on all physician visits, hospital admissions, and dispensed medications, linked to a perinatal registry with valid information on date of conception. We created a pregnancy cohort of women with inflammatory arthritis (IA) using a case definition of 2 ICD9 codes: ≥2 months and ≥2 years apart for rheumatoid arthritis, systemic autoimmune rheumatic diseases, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. We categorised csDMARDs according to accepted safety profiles: Group 1 - antimalarials, cyclosporine-A, gold, and sulfasalazine; and psoriatic arthritis. We categorised csDMARDs according to accepted safety profiles: Group 1 - antimalarials, cyclosporine-A, gold, and sulfasalazine; and psoriatic arthritis. We categorised csDMARDs according to accepted safety profiles: Group 1 - antimalarials, cyclosporine-A, gold, and sulfasalazine; and psoriatic arthritis. We categorised csDMARDs according to accepted safety profiles: Group 1 - antimalarials, cyclosporine-A, gold, and sulfasalazine; and psoriatic arthritis.

Results: 1 MCM identified

Abstract THU0697 – Table 1. Baseline diagnosis before first NVC.

Abstract THU0697 – Table 2. Patients whose NVC progresses, patterns and related autoantibodies.